within Pharmacolibrary.Drugs.ATC.R;

model R03DC53
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.64,
    Cl             = 0.7583333333333333,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.0087,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.028833333333333332,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Montelukast, in combination with other agents, is used as a leukotriene receptor antagonist for the maintenance treatment of asthma and the relief of symptoms of allergic rhinitis. The combinations are generally used in patients for whom monotherapy is not sufficient. Montelukast combinations are not widely approved for use today as fixed combinations, but montelukast itself is approved.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters for montelukast (with combination, all sexes, adults, assuming similar PK as monotherapy; limited published PK data exist for fixed combinations).</p><h4>References</h4><ol><li><p>Moon, SJ, et al., &amp; Kim, MG (2020). Comparative pharmacokinetics of a montelukast/levocetirizine fixed-dose combination chewable tablet versus individual administration of montelukast and levocetirizine after a single oral administration in healthy Korean male subjects . <i>International journal of clinical pharmacology and therapeutics</i> 58(6) 354–362. DOI:<a href=&quot;https://doi.org/10.5414/CP203709&quot;>10.5414/CP203709</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32271144/&quot;>https://pubmed.ncbi.nlm.nih.gov/32271144</a></p></li><li><p>Kim, S, et al., &amp; Kim, JR (2018). Comparison of the pharmacokinetics and tolerability of montelukast/levocetirizine administered as a fixed-dose combination and as separate tablets. <i>International journal of clinical pharmacology and therapeutics</i> 56(9) 443–450. DOI:<a href=&quot;https://doi.org/10.5414/CP203265&quot;>10.5414/CP203265</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30021691/&quot;>https://pubmed.ncbi.nlm.nih.gov/30021691</a></p></li><li><p>Böhmer, GM, et al., &amp; Hermann, R (2009). The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions. <i>Journal of clinical pharmacology</i> 49(4) 389–397. DOI:<a href=&quot;https://doi.org/10.1177/0091270008330980&quot;>10.1177/0091270008330980</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19318692/&quot;>https://pubmed.ncbi.nlm.nih.gov/19318692</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03DC53;
